@article{52a43f9b551f439db2387988cf5ae87a,
title = "Developing a crosswalk between the RAND-12 and the health utilities index for multiple sclerosis",
abstract = "Background: Researchers studying health-related quality of life (HRQOL) in multiple sclerosis (MS) can choose from many instruments, but findings from studies which use different instruments cannot be easily combined. We aimed to develop a crosswalk that associates scores from the RAND-12 to scores on the Health Utilities Index—Mark III (HUI3) in persons with MS. Methods: In 2018, participants in the North American Research Committee on Multiple Sclerosis (NARCOMS) registry completed the RAND-12 and the HUI3 to assess HRQOL. We used item-response theory (IRT) and equipercentile linking approaches to develop a crosswalk between instruments. We compared predicted scores for the HUI3 from each crosswalk to observed scores using Pearson correlations, intraclass correlation coefficients (ICCs), and Bland–Altman plots. Results: Of 11,389 invited participants, 7129 (62.6%) responded. Predicted and observed values of the HUI3 from the IRT-linking method were moderately correlated (Pearson r = 0.76) with good concordance (ICC = 0.72). However, the Bland–Altman plots suggested biased prediction. Predicted and observed values from the equipercentile linking method were also moderately correlated (Pearson r = 0.78, ICC = 0.78). The Bland–Altman plots suggested no bias. Conclusion: We developed a crosswalk between the RAND-12 and the HUI3 in the MS population which will facilitate data harmonization efforts.",
keywords = "Multiple sclerosis, health utilities index, quality of life",
author = "Marrie, {Ruth Ann} and Brenden Dufault and Tuula Tyry and Cutter, {Gary R.} and Fox, {Robert J.} and Amber Salter",
note = "Funding Information: The author(s) declared receipt of the following financial support for the research, authorship, and/or publication of this article: NARCOMS is funded in part by the CMSC and the Foundation of the CMSC. The study was also supported in part by the Waugh Family Chair in Multiple Sclerosis (to RAM). The funding source(s) had no role in the study design, collection, analysis or interpretation of the data, nor in the decision to submit the article for publication. Funding Information: The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: R.F. receives consultant fees from Actelion, Biogen, Genentech, Novartis, and Teva. He has served on advisory committees for Biogen and Novartis. He also receives research support from Biogen (clinical trial contracts) and Novartis (research study support). G.R.C. serves on Data and Safety Monitoring Boards for AMO Pharmaceuticals, Apotek, Gilead Pharmaceuticals, Horizon Pharmaceuticals, Modigenetech/Prolor, Merck, Merck/Pfizer, Opko Biologics, Neurim, Sanofi-Aventis, Reata Pharmaceuticals, Receptos/Celgene, Teva pharmaceuticals, NHLBI (Protocol Review Committee), NICHD (OPRU oversight committee). He also serves on consulting or advisory boards for Atara Biotherapeutics, Bioeq GmBH, Cerespir Inc, Consortium of MS Centers (grant), Genzyme, Genentech, Innate Therapeutics, Jannsen Pharmaceuticals, Klein-Buendel Incorporated, Medimmune, Medday, Nivalis, Novartis, Opexa Therapeutics, Roche, Savara Inc., Somahlution, Teva pharmaceuticals, Transparency Life Sciences, and TG Therapeutics. R.A.M. receives research funding from CIHR, the National MS Society, the MS Society of Canada, the MS Scientific Research Foundation, Research Manitoba, the Consortium of MS Centers, Crohn{\textquoteright}s and Colitis Canada and the Waugh Family Chair in Multiple Sclerosis. The remaining authors have nothing to disclose. Publisher Copyright: {\textcopyright} The Author(s), 2019.",
year = "2020",
month = aug,
day = "1",
doi = "10.1177/1352458519852722",
language = "English (US)",
volume = "26",
pages = "1102--1110",
journal = "Multiple Sclerosis",
issn = "1352-4585",
publisher = "SAGE Publications Ltd",
number = "9",
}